Takeda has scrapped plans to develop TAK-128 for diabetic neuropathy and canceled its licensing pact with Mitsubishi after a mid-stage trial failed to demonstrate significant efficacy. And, as expected, Takeda also canceled a pact with BioNumerik Pharmaceuticals for Tavocept for the Japanese market. Takeda canceled the Tavocept agreement for the U.S. and Canada a week ago. Takeda announced last July that Tavocept had failed two late-stage trials for severe neuropathy. KI Pharma and ASKA will continue to be involved with Tavocept in Japan. Almost simultaneously, Takeda announced it had inked a pact with Xoma to discover and develop therapeutic antibodies that would be worth up to $100 million before royalties. Xoma will use its antibody technology to select antibodies for Takeda's targets.